@article{b238e7380f5a4679a6508bafabe5ae17,
title = "A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder",
keywords = "Bladder cancer, Cisplatin ineligible, Immune checkpoint inhibitors, Metastatic bladder squamous cell carcinoma, PD-1 inhibitor, Psuedoprogression",
author = "Chester Kao and Megan McNamara and Chris Alley and Neil Spector and Shekeab Jauhari and Gupta, {Rajan T.} and Tian Zhang and Jason Zhu",
note = "Funding Information: T. Zhang reports research funding from Merck, Acerta, Novartis, Merrimack, Abbvie, Regeneron, Janssen, Pfizer, OmniSeq, and PGDx; consulting fees from Genentech Roche, Exelixis, Sanofi-Aventis, Bayer, Janssen, Astra Zeneca, Pfizer, Amgen, BMS, and Foundation Medicine; and speakers bureau for Exelixis, Genentech Roche, Sanofi Aventis, and Genomic Health. The remaining authors have stated that they have no conflicts of interest. Funding Information: T. Zhang reports research funding from Merck , Acerta , Novartis , Merrimack , Abbvie , Regeneron , Janssen , Pfizer , OmniSeq , and PGDx ; consulting fees from Genentech Roche, Exelixis, Sanofi-Aventis, Bayer, Janssen, Astra Zeneca, Pfizer, Amgen, BMS, and Foundation Medicine; and speakers bureau for Exelixis, Genentech Roche, Sanofi Aventis, and Genomic Health. The remaining authors have stated that they have no conflicts of interest.",
year = "2019",
month = jun,
doi = "10.1016/j.clgc.2019.03.019",
language = "English (US)",
volume = "17",
pages = "e672--e677",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "3",
}